Antiresorptive agents, raloxifene, and PHARMAC

New Zealand Medical Journal

Volumn 119, Issue 1230, 2006, Pages

  Gilchrist, Nigel L ^a  

^a PRINCESS MARGARET HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; ETIDRONIC ACID; PARATHYROID HORMONE; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; VITAMIN D DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FRAGILITY FRACTURE; HEALTH CARE ORGANIZATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; AGED; DRUG APPROVAL; DRUG SCREENING; FEMALE; METHODOLOGY; NEW ZEALAND; PATHOLOGIC FRACTURE; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; BONE DENSITY CONSERVATION AGENTS; DRUG APPROVAL; DRUG EVALUATION; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; NEW ZEALAND; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33645226951     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lane A. Direct costs of osteoporosis for New Zealand women. Pharmacoeconomics. 1996:3;231-45.
2. Harris ST, Watts, NB, Genant H,K et al. Effect of risedronate treatment on vertebral and nonvertebral fractures in women with post menopausal osteoporosis a randomised controlled trial. JAMA. 1999;282:1344-52.
3. McClung MR, Geusens P, Miller P, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344;333-40.
4. Ettinger B, Black DM, Mitlik BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3 year randomised clinical trial. JAMA. 1999:282;637-45.
5. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med. 2004:350;459-68.
6. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in women aged 80 and older: implications for the use of anti-resorptive agents in the old and oldest old. J Am Geriatric Soc. 2004:52:1832-9.
7. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post menopausal osteoporosis. N Engl J Med. 1995:333;1437-43.
8. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years results from the continuing outcomes relevant to Evista (CORE) study. J Bone Mineral Res. 2005:20;1514-24.
9. Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the raloxifene use for the heart (RUTH) trial. Am J Cardiol. 2002:90;1204-10.
10. Delmas PD, Seeman E. Changes in bone density explain little of the reduction in vertebral fracture risk with anti-resorptive therapy. Bone. 2004;34;599-604.
11. Kanis JA, Borgstrom F, Jornell O, et al. Cost effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis Int. 2005:16;15-25.